Page last updated: 2024-11-05

thalidomide and Lymphoma, T Cell, Peripheral

thalidomide has been researched along with Lymphoma, T Cell, Peripheral in 14 studies

Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.

Research Excerpts

ExcerptRelevanceReference
" Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])."9.22Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016)
" Of 13 assessable patients (nine with adult T-cell leukaemia-lymphoma, four with other peripheral T-cell lymphomas) receiving lenalidomide, dose-limiting toxic effects were reported in three patients during cycle 1 (one grade 4 thrombocytopenia [cohort 2], one grade 3 QT prolongation on electrocardiogram [cohort 3], and one grade 3 fatigue and grade 4 thrombocytopenia [cohort 3])."5.22Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study. ( Aoki, T; Asou, N; Chen, N; Choi, I; Imaizumi, Y; Maruyama, D; Midorikawa, S; Nosaka, K; Ogura, M; Ohtsu, T; Taguchi, J; Tobinai, K; Tsukasaki, K; Uchida, T; Uike, N; Utsunomiya, A, 2016)
" Haemocytopenia was the predominant adverse effect, and acute toxicity was moderate, tolerable and well managed in both arms."2.84The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers. ( Chang, Y; Duan, W; Fu, X; Li, L; Li, X; Li, Z; Nan, F; Sun, Z; Wang, X; Wu, J; Yan, J; Young, KH; Zhang, L; Zhang, M; Zhang, X, 2017)
" In conclusion, the poor results obtained with lenalidomide in combination with vorinostat and dexamethasone provide no arguments that could justify further investigation of this drug combination for the treatment of relapsed PTCL."2.79Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. ( Egle, A; Greil, R; Hopfinger, G; Lang, A; Linkesch, W; Melchardt, T; Nösslinger, T; Weiss, L, 2014)
"Patients received oral lenalidomide 25mg once daily on days 1-21 of each 28-day cycle for a maximum of 24 months, until disease progression or development of unacceptable adverse events (AEs)."2.78A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial. ( Bosly, A; Coiffier, B; Delarue, R; Fitoussi, O; Gabarre, J; Glaisner, S; Haioun, C; Li, J; Lister, J; Morschhauser, F; Quach, H; Thieblemont, C, 2013)
"We report the cases of 3 patients with hematological malignancies and complex karyotypes involving der(5; 17) (p10;q10), which results in the loss of 5q and 17p."2.50der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases. ( Aoyama, Y; Furukawa, Y; Harada, N; Kumura, T; Manabe, M; Mugitani, A; Ohta, T; Okita, J; Tarakuwa, T, 2014)
"Lenalidomide treatment demonstrated for the first time in the literature impressive and long-term clinical efficacy in a heavily pretreated chemorefractory AITL patient."1.39Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up. ( Bocchia, M; Cencini, E; Defina, M; Fabbri, A; Fontanelli, G; Gozzetti, A; Mazzei, MA; Pietrini, A; Volterrani, L, 2013)

Research

Studies (14)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (14.29)29.6817
2010's11 (78.57)24.3611
2020's1 (7.14)2.80

Authors

AuthorsStudies
Wang, Y1
Zhang, M2
Song, W1
Cai, Q1
Zhang, L2
Sun, X1
Zou, L1
Zhang, H1
Wang, L1
Xue, H1
Li, L1
Duan, W1
Li, X1
Fu, X1
Wang, X1
Wu, J1
Sun, Z1
Zhang, X1
Chang, Y1
Nan, F1
Yan, J1
Li, Z1
Young, KH1
Morschhauser, F2
Fitoussi, O1
Haioun, C1
Thieblemont, C1
Quach, H1
Delarue, R1
Glaisner, S1
Gabarre, J1
Bosly, A1
Lister, J1
Li, J1
Coiffier, B2
Hopfinger, G1
Nösslinger, T1
Lang, A1
Linkesch, W1
Melchardt, T1
Weiss, L1
Egle, A1
Greil, R1
Manabe, M1
Okita, J1
Tarakuwa, T1
Harada, N1
Aoyama, Y1
Kumura, T1
Ohta, T1
Furukawa, Y1
Mugitani, A1
Federico, M1
Caballero, D1
Dearden, C1
Jäger, U1
Trümper, L1
Zucca, E1
Gomes da Silva, M1
Pettengell, R1
Weidmann, E1
d'Amore, F1
Tilly, H1
Zinzani, PL2
Toumishey, E1
Prasad, A1
Dueck, G1
Chua, N1
Finch, D1
Johnston, J1
van der Jagt, R1
Stewart, D1
White, D1
Belch, A1
Reiman, T1
Ogura, M1
Imaizumi, Y1
Uike, N1
Asou, N1
Utsunomiya, A1
Uchida, T1
Aoki, T1
Tsukasaki, K1
Taguchi, J1
Choi, I1
Maruyama, D1
Nosaka, K1
Chen, N1
Midorikawa, S1
Ohtsu, T1
Tobinai, K1
Gottardi, M1
Danesin, C1
Canal, F1
Dei Tos, AP1
Stefani, PM1
Calistri, E1
Salvadori, U1
Gherlinzoni, F1
O'Connor, OA1
Qin, Y1
Shi, YK1
He, XH1
Yang, JL1
Zhang, CG1
Zhou, SY1
Liu, XF1
Liu, P1
Yang, S1
Zhou, LQ1
Han, XH1
Yao, JR1
Pellegrini, C1
Broccoli, A1
Stefoni, V1
Gandolfi, L1
Quirini, F1
Argnani, L1
Berti, E1
Derenzini, E1
Pileri, S1
Baccarani, M1
Fabbri, A1
Cencini, E1
Pietrini, A1
Gozzetti, A1
Defina, M1
Fontanelli, G1
Mazzei, MA1
Volterrani, L1
Bocchia, M1
Ramasamy, K1
Lim, Z1
Pagliuca, A1
Salisbury, JR1
Mufti, GJ1
Devereux, S1

Clinical Trials (8)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma, a Multicentric, Single Arm, Open Label Phase II Clinical Trial[NCT03273452]Phase 230 participants (Anticipated)Interventional2017-03-01Recruiting
A Randomized Controlled Multi-center Clinical Trial on Treatment of Peripheral T-cell Lymphoma With DGPT Regiment (Gemcitabine,Cisplatin,Prednisone ,Thalidomide )[NCT01664975]Phase 4100 participants (Actual)Interventional2011-08-31Completed
A Phase II, Prospective, Single-center Study of Lenalidomide in Combination With CHOP in Patients With Untreated PTCL[NCT04423926]Phase 1/Phase 291 participants (Anticipated)Interventional2020-06-10Recruiting
A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid®) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma[NCT00655668]Phase 254 participants (Actual)Interventional2008-03-01Terminated (stopped due to Decision not to pursue as single agent in the study population.)
Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.[NCT03964480]1,000 participants (Anticipated)Observational [Patient Registry]2018-10-14Recruiting
A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma[NCT00322985]Phase 240 participants (Actual)Interventional2006-06-30Completed
A Phase I, Multicenter, Open-label, Dose-escalation Study to Assess the Safety of Lenalidomide in Patients With Advanced Adult T-cell Leukemia-lymphoma and Peripheral T-cell Lymphoma[NCT01169298]Phase 113 participants (Actual)Interventional2010-07-01Completed
[NCT01036399]Phase 29 participants (Actual)Interventional2008-11-30Terminated (stopped due to The EC withdrawn the approval becuase of possible conflicts of interests between our Institute and Supporter (Celgene))
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Progression-free Survival

(NCT01664975)
Timeframe: up to end of follow-up-phase (approximately 24 months)

Interventionparticipants (Number)
GDPT Regimen35
CHOP Regimen27

Duration of Response

Kaplan-Meier Estimate of duration of response calculated as the time from first computed tomography (CT) Scan or magnetic resonance imaging (MRI) that demonstrates at least a partial response to the first documentation of disease progression, including death due to Non-Hodgkin's Lymphoma. (NCT00655668)
Timeframe: Up to 24 months

InterventionMonths (Median)
Single Agent Lenalidomide3.55

Progression-Free Survival

Kaplan-Meier estimate of progression-free survival is defined as the start of study drug therapy to the first observation of disease progression or death due to any cause. (NCT00655668)
Timeframe: Up to 24 months

InterventionMonths (Median)
Single Agent Lenalidomide2.53

Participants Categorized by Best Response as Determined by Investigator

"Participant response assessed by investigator; criteria by B. Cheson in Journal of Clinical Oncology, 1999 (see article for more detail):~Complete Response(CR): Complete disappearance of all detectable disease~Complete Response Unconfirmed(CRu): CR, but indeterminate bone marrow~Partial Response(PR): >50% decrease in six largest nodes/nodal masses~Stable Disease(SD): Less than PR, but not progressive disease~Relapsed Disease: In CR/CRu Patients, new lesions seen or increased by >=50% in previous sites~Progressive Disease(PD): >=50% increase from low in PR/Non-Responders" (NCT00655668)
Timeframe: Up to 24 months

InterventionParticipants (Number)
Complete Response (CR)Complete Response Unconfirmed (CRu)Partial Response (PR)Stable Disease (SD)Progressive Disease (PD)No Response AssessmentOtherTumor Control (CR+CRu+PR+SD)
Single Agent Lenalidomide42616169128

Safety

Summary of Treatment-Emergent Events in Safety Population (participants with at least one dose of study drug). Events assessed using National Cancer Institute, Common Terminology Criteria for Adverse Events (NCI CTCAE, Version 3: Following is the scale: Grade 1=Mild Adverse Event (AE), Grade 2=Moderate AE, Grade 3=Severe and Undesirable AE, Grade 4=Life-threatening or Disabling AE, and Grade 5=Death Related to AE.) (NCT00655668)
Timeframe: Up to 24 months

InterventionParticipants (Number)
At least 1 adverse event (AE)At least 1 AE related to drugAt least 1 NCI CTCAE Grade 3-4 AEAt least 1 NCI CTCAE Gr 3-4 AE related to drugAt least 1 serious adverse event (SAE)At least 1 SAE related to drugAt least 1 AE leading to drug withdrawal (WD)At least 1 AE leading to drug interruption/WD
Single Agent Lenalidomide5340341929162119

Reviews

3 reviews available for thalidomide and Lymphoma, T Cell, Peripheral

ArticleYear
der(5;17)(p10;q10) is a recurrent but rare whole-arm translocation in patients with hematological neoplasms: a report of three cases.
    Acta haematologica, 2014, Volume: 132, Issue:2

    Topics: Aged; Aged, 80 and over; Anemia, Refractory, with Excess of Blasts; Aneuploidy; Antineoplastic Combi

2014
Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Cancer treatment reviews, 2014, Volume: 40, Issue:9

    Topics: Alemtuzumab; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemo

2014
Novel agents in development for peripheral T-cell lymphoma.
    Seminars in hematology, 2010, Volume: 47 Suppl 1

    Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemoth

2010

Trials

7 trials available for thalidomide and Lymphoma, T Cell, Peripheral

ArticleYear
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial.
    American journal of hematology, 2022, Volume: 97, Issue:5

    Topics: Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Etoposide; Humans; Lymph

2022
The efficacy and safety of gemcitabine, cisplatin, prednisone, thalidomide versus CHOP in patients with newly diagnosed peripheral T-cell lymphoma with analysis of biomarkers.
    British journal of haematology, 2017, Volume: 178, Issue:5

    Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cisplati

2017
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
A phase 2, multicentre, single-arm, open-label study to evaluate the safety and efficacy of single-agent lenalidomide (Revlimid) in subjects with relapsed or refractory peripheral T-cell non-Hodgkin lymphoma: the EXPECT trial.
    European journal of cancer (Oxford, England : 1990), 2013, Volume: 49, Issue:13

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Disease Progression;

2013
Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial.
    Annals of hematology, 2014, Volume: 93, Issue:3

    Topics: Aged; Angiogenesis Inhibitors; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy

2014
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Cancer, 2015, Mar-01, Volume: 121, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Surviva

2015
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Cancer, 2015, Mar-01, Volume: 121, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Surviva

2015
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Cancer, 2015, Mar-01, Volume: 121, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Surviva

2015
Final report of a phase 2 clinical trial of lenalidomide monotherapy for patients with T-cell lymphoma.
    Cancer, 2015, Mar-01, Volume: 121, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Disease-Free Surviva

2015
Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
    The Lancet. Haematology, 2016, Volume: 3, Issue:3

    Topics: Adult; Angiogenesis Inhibitors; Humans; Lenalidomide; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-C

2016
Lenalidomide monotherapy for relapsed/refractory peripheral T-cell lymphoma not otherwise specified.
    Leukemia & lymphoma, 2011, Volume: 52, Issue:8

    Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Agents; Dose-Response Relationship, Dr

2011

Other Studies

4 other studies available for thalidomide and Lymphoma, T Cell, Peripheral

ArticleYear
Complete remission induced by thalidomide in a case of angioimmunoblastic T-cell lymphoma refractory to autologous stem cell transplantation.
    Leukemia & lymphoma, 2008, Volume: 49, Issue:9

    Topics: Hematopoietic Stem Cell Transplantation; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell, Pe

2008
[Clinical features and prognostic factors of angioimmunoblastic T cell lymphoma].
    Zhonghua zhong liu za zhi [Chinese journal of oncology], 2010, Volume: 32, Issue:6

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxo

2010
Impressive activity of lenalidomide monotherapy in refractory angioimmunoblastic T-cell lymphoma: report of a case with long-term follow-up.
    Hematological oncology, 2013, Volume: 31, Issue:4

    Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; C

2013
Successful treatment of refractory angioimmunoblastic T-cell lymphoma with thalidomide and dexamethasone.
    Haematologica, 2006, Volume: 91, Issue:8 Suppl

    Topics: Adult; Angiogenesis Inhibitors; Dexamethasone; Drug Therapy, Combination; Humans; Lymphoma, T-Cell,

2006
chemdatabank.com